#United States #San Diego #Robbins LLP #Stockholder Rights #GeneDx Holdings

Recent Class Action Lawsuit Alerts GeneDx Holdings Corp. Stockholders

On June 8, 2026, Robbins LLP announced a class action lawsuit aimed at protecting the rights of stockholders of GeneDx Holdings Corp. (NASDAQ: WGS). This case pertains to individuals who acquired stock between April 16, 2025, and May 4, 2026. GeneDx, known for its provision of genetic testing services focused on pediatric and rare diseases, is now under scrutiny for its business practices.

Key Allegations

The law firm Robbins LLP highlights concerns that GeneDx misled investors regarding the acquisition of Fabric Genomics, a company focused on AI-driven genomic interpretations. The transaction was valued at approximately $51 million and was touted to significantly enhance GeneDx's business model through multiple scalable revenue streams. However, allegations suggest that the statements made by GeneDx on the potential benefits of this acquisition were materially false and misleading.

During the acquisition announcement in April 2025, GeneDx indicated that the integration of Fabric would create efficiencies and improve its financial performance. However, internal claims later indicated that the company was aware of substantial issues concerning Fabric's viability which could adversely affect GeneDx’s operations. This apparent failure to disclose critical information led to a significant downturn in GeneDx's stock price.

On May 4, 2026, after the reporting of financial results for the first quarter, GeneDx revealed it had missed revenue estimates for both exome and genome testing lines. The organization also revised its revenue guidance for the fiscal year downward—from projected earnings of $540 million-$550 million to $475 million-$490 million. Furthermore, a notable impairment loss of $31.2 million linked to the Fabric acquisition was announced. These disclosures triggered a dramatic drop in GeneDx's stock, plummeting by $33.42 per share, which is a staggering decline of 49.2%.

Implications for Shareholders

This class action lawsuit underscores the importance of holding companies accountable for their statements to investors. If you were a shareholder during the specified period and believe you may have been adversely affected by these misleading communications, you could be eligible to participate in the ongoing legal proceedings. Shareholders interested in taking a more active role, possibly as lead plaintiffs, are encouraged to reach out to Robbins LLP for further guidance. Being a lead plaintiff allows representation of the class in legal matters, although shareholders may also choose to remain passive participants without taking legal action.

Robbins LLP operates on a contingency fee basis, which means that shareholders will incur no direct legal fees unless they recover losses through the case. Such arrangements make it easier for investors to seek justice without financial strain, ensuring broader accessibility to legal recourse.

About Robbins LLP

Robbins LLP has been a prominent advocate for shareholders since 2002, focusing on litigation involving corporate governance and the accountability of executives. Their efforts are aimed at helping shareholders reclaim losses while fostering improved governance practices in corporations. The firm encourages all affected shareholders to consider the implications of their investments and to stay informed about developments in their legal rights related to GeneDx and similar cases.

For updates regarding the progress of this class action or to receive notifications about potential settlements, interested parties can sign up for Stock Watch alerts from Robbins LLP.

Note: Participation in the ongoing lawsuit is confirmed by reaching out to the firm directly and is not mandatory for shareholders who wish to remain uninvolved. Past performance success does not guarantee similar outcomes in future cases.